






Role of pharmacists in effective COPD management




Impact of COPD in the USA



Goals for treatment of stable COPD⁵



As an integral member of the team, pharmacists coordinate with other HCPs to drive patient care^{6,7,8}



Challenges in COPD management resulting in poor clinical and economic outcomes

Pharmacist-led interventions that could improve treatment outcomes

- Underutilization of spirometry in primary care⁹



Screening for symptoms and risk factors in at-risk individuals to enable timely diagnosis⁶



Collaboration with physicians for spirometric assessment⁹

- Polypharmacy¹⁰
- Improper inhaler technique¹¹



Medication reconciliation to reduce errors and support safe use¹²



Patient counseling for proper inhaler technique¹³



Implementing patient-centric written action plan^{14,15}

- Nonadherence to prescribed regimen¹⁴
- Adverse drug events¹⁰



Reviewing inhaler technique and medication adherence^{13,16}



Providing cost-based reducing alternatives and reducing the risk of adverse drug events¹⁷



Reviewing action plan^{14,15}

- COPD exacerbations⁴
- Increased risk due to comorbidities¹⁸
- Self-management of COPD⁵

Strategies for self-management and exacerbation reduction



Encouraging lifestyle changes⁶



Discussing prevention strategies e.g., vaccination⁶



Educating about risk factors and comorbidities⁶

Disclosure: The author meets the criteria for authorship as recommended by the International Committee of Medical Journal Editors. The author received no direct compensation related to the development of the infographic. Writing, editorial, and formatting assistance was provided by Cactus Communications, which was contracted and compensated by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). BIPI was given the opportunity to review the infographic for medical and scientific accuracy as well as intellectual property considerations.

Abbreviations: COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HCP, health care provider; USA, United States of America.
References: 1. Ghosh S et al. *J Aerosol Med Pulm Drug Deliv.* 2017;30:381-7; 2. Fact sheet - Chronic Obstructive Pulmonary Disease (COPD). *NIH;* 2010; 3. Ford ES et al. *Chest.* 2015;147:31-45; 4. Perera PN et al. *COPD.* 2012; 9:131-41; 5. GOLD 2019. Accessed June 29, 2019; 6. American Pharmacists Association Foundation. *J Am Pharm Assoc.* 2003. 2011;51:203-11; 7. van der Molen T et al. *Br J Clin Pharmacol.* 2017;83:192-201; 8. Cavanaugh JJ et al. *J Manag Care Spec Pharm.* 2015;21:256-60; 9. Cawley MJ et al. *Pharm Pract (Granada).* 2011;9:221-7; 10. Diez-Manglano J et al. *Eur Respir J.* 2014;44:791-4; 11. Sanchis J et al. *Chest.* 2016;150:394-406; 12. ASHP statement. *Am J Health Syst Pharm.* 2013; 70:453-6.; 13. Nguyen TS et al. *Int J Chron Obstruct Pulmon Dis.* 2018;13:1863-72; 14. National Heart Lung, and Blood Institute. COPD National Action Plan. 2017. Accessed June 29, 2019; 15. Bryant J et al. *Respir Res.* 2013;14:109; 16. van Boven JF et al. *J Allergy Clin Immunol Pract.* 2016;4:835-46; 17. Dalton K and Byrne S. *Integr Pharm Res Pract.* 2017;6:37-46; 18. Divo MJ et al. *Eur Respir J.* 2014;44:1055-68.